Endometrial carcinoma
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DIS-ENDOMETRIAL |
|---|---|
| Type | Disease |
| Aliases | Endometrial cancerUterine cancerКарцинома ендометрія |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-ENDOMETRIAL-2022 SRC-NCCN-UTERINE-2025 |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 8380/3 |
|---|---|
| icd_o_3_topography | ["C54.1"] |
| icd_10 | C54 |
| who_classification | Endometrial adenocarcinoma + TCGA molecular classification (WHO 5th 2020) |
Notes
biomarker_driven — TCGA molecular classification dominant stratifier. dMMR drives largest ICI benefit.
Used By
Actionability
BMA-CTNNB1-ENDOMETRIAL- CTNNB1 exon 3 mutations occur in ~25–30% of endometrial carcinoma (EC), predominantly end...BMA-EPCAM-GERMLINE-ENDOMETRIAL- EPCAM germline deletion silences MSH2 → Lynch syndrome with dMMR endometrial cancer pheno...BMA-FGFR2-MUTATION-ENDOMETRIAL- FGFR2 mutation in endometrial carcinoma (~10-12% endometrioid histology). Pemigatinib and...BMA-KRAS-G12C-ENDOMETRIAL- KRAS mutations occur in ~15-25% of endometrioid endometrial cancers; G12C is a minority s...BMA-KRAS-G12D-ENDOMETRIAL- KRAS G12D in endometrial — common in endometrioid; no approved targeted therapy.BMA-KRAS-G12V-ENDOMETRIAL- KRAS G12V in endometrial — POLE/MMR/p53 subtyping drives 1L.BMA-MLH1-GERMLINE-ENDOMETRIAL- MLH1 germline loss-of-function in endometrial produces dMMR/MSI-H phenotype. Pan-tumor MS...BMA-MLH1-SOMATIC-ENDOMETRIAL- MLH1 somatic loss-of-function in endometrial produces dMMR/MSI-H phenotype. Pan-tumor MSI...BMA-MSH2-GERMLINE-ENDOMETRIAL- MSH2 germline loss-of-function in endometrial produces dMMR/MSI-H phenotype. Pan-tumor MS...BMA-MSH2-SOMATIC-ENDOMETRIAL- MSH2 somatic loss-of-function in endometrial produces dMMR/MSI-H phenotype. Pan-tumor MSI...BMA-MSH6-GERMLINE-ENDOMETRIAL- MSH6 germline loss-of-function in endometrial produces dMMR/MSI-H phenotype. Pan-tumor MS...BMA-MSH6-SOMATIC-ENDOMETRIAL- MSH6 somatic loss-of-function in endometrial produces dMMR/MSI-H phenotype. Pan-tumor MSI...BMA-MSI-STATUS-ENDOMETRIAL- MSI-H/dMMR endometrial cancer (~25-30% of advanced cases) qualifies for ICI-based regimen...BMA-PIK3CA-HOTSPOT-ENDOMETRIAL- PIK3CA mutations occur in ~30-50% of endometrioid endometrial cancers, often co-occurring...BMA-PIK3R1-ENDOMETRIAL- PIK3R1 mutations occur in ~33% of endometrial carcinoma (EC) — among the highest frequenc...BMA-PMS2-GERMLINE-ENDOMETRIAL- PMS2 germline loss-of-function in endometrial produces dMMR/MSI-H phenotype. Pan-tumor MS...BMA-PMS2-SOMATIC-ENDOMETRIAL- PMS2 somatic loss-of-function in endometrial produces dMMR/MSI-H phenotype. Pan-tumor MSI...BMA-TP53-IHC-ENDOMETRIAL- p53-aberrant (p53-abn) endometrial carcinoma defines the highest-risk molecular subgroup...BMA-TP53-MUT-ENDOMETRIAL- TP53 mutation in ENDOMETRIAL — common, adverse prognostic; not directly targeted. Per usu...
Algorithms
ALGO-AMSTERDAM-II-LYNCH- ALGO-AMSTERDAM-II-LYNCHALGO-COWDEN-CARRIER-SURVEILLANCE- ALGO-COWDEN-CARRIER-SURVEILLANCEALGO-ENDOMETRIAL-2L- ALGO-ENDOMETRIAL-2LALGO-ENDOMETRIAL-ADVANCED-1L- ALGO-ENDOMETRIAL-ADVANCED-1LALGO-PEUTZ-JEGHERS-CARRIER-SURVEILLANCE- ALGO-PEUTZ-JEGHERS-CARRIER-SURVEILLANCE
Disease
DIS-LEIOMYOSARCOMA- Leiomyosarcoma (LMS)
Indication
IND-ENDOMETRIAL-2L-DOSTARLIMAB-DMMR- IND-ENDOMETRIAL-2L-DOSTARLIMAB-DMMRIND-ENDOMETRIAL-2L-PEMBRO-LENVA-PMMR- IND-ENDOMETRIAL-2L-PEMBRO-LENVA-PMMRIND-ENDOMETRIAL-ADVANCED-1L-DOSTARLIMAB-CHEMO- IND-ENDOMETRIAL-ADVANCED-1L-DOSTARLIMAB-CHEMOIND-ENDOMETRIAL-ADVANCED-1L-PEMBRO-CHEMO- IND-ENDOMETRIAL-ADVANCED-1L-PEMBRO-CHEMOIND-ENDOMETRIAL-STAGE-I-POLE-OBSERVATION- IND-ENDOMETRIAL-STAGE-I-POLE-OBSERVATIONIND-IATROGENIC-TAMOXIFEN-ENDOMETRIAL-PREVENTION-OBSERVATION- IND-IATROGENIC-TAMOXIFEN-ENDOMETRIAL-PREVENTION-OBSERVATIONIND-IATROGENIC-TAMOXIFEN-ENDOMETRIAL-PREVENTION-SURVEILLANCE- IND-IATROGENIC-TAMOXIFEN-ENDOMETRIAL-PREVENTION-SURVEILLANCEIND-REPRODUCTIVE-PCOS-ENDOMETRIAL-PREVENTION-OBSERVATION- IND-REPRODUCTIVE-PCOS-ENDOMETRIAL-PREVENTION-OBSERVATIONIND-REPRODUCTIVE-PCOS-ENDOMETRIAL-PREVENTION-SURVEILLANCE- IND-REPRODUCTIVE-PCOS-ENDOMETRIAL-PREVENTION-SURVEILLANCE
Procedures
PROC-GENETIC-COUNSELING-PRE-TEST- Pre-test genetic counseling encounter for germline cancer-susceptibility testingPROC-PROPHYLACTIC-HYSTERECTOMY-LYNCH- Risk-reducing hysterectomy with or without BSO in Lynch syndrome carriers
Questionnaires
QUEST-ENDOMETRIAL-1L-STUB- Endometrial carcinoma — first line
Red flag
RF-ACTIVE-AUTOIMMUNE-DISEASE-ICI-RISK- Patient with active or incompletely controlled pre-existing autoimmune or inflammatory di...RF-CASCADE-LYNCH-FDR-POSITIVE- A first-degree relative of the patient (parent, sibling, or child) has a documented posit...RF-CHRONIC-SEVERE-OBESITY-BMI40-PREVENTION- Severe obesity — BMI ≥40 kg/m² (WHO class III obesity), distinct from the broader RF-LIFE...RF-CHRONIC-T2DM-CANCER-RISK-PREVENTION- Established type-2 diabetes mellitus (HbA1c ≥6.5% on two occasions, or established T2DM d...RF-COWDEN-CONFIRMED-CARRIER- Confirmed germline pathogenic / likely-pathogenic variant in the PTEN gene (Cowden syndro...RF-COWDEN-FAMILY-HISTORY-SUSPICION- Family pedigree suggestive of Cowden syndrome / PTEN hamartoma tumor syndrome (PHTS): any...RF-ENDOMETRIAL-FIT-FOR-LENVATINIB-COMBO- Endometrial carcinoma 2L candidate with adequate organ function and controllable comorbid...RF-ENDOMETRIAL-FRAILTY-AGE- Frailty profile precluding standard carbo+pacli ± pembro / dostarlimab in advanced/recurr...RF-ENDOMETRIAL-HIGH-RISK-BIOLOGY- dMMR/MSI-high OR p53-abnormal OR POLE-mutated — TCGA classification drives ICI eligibilit...RF-ENDOMETRIAL-INFECTION-SCREENING- Active or latent infection requiring resolution / prophylaxis before initiating cytotoxic...RF-ENDOMETRIAL-ORGAN-DYSFUNCTION- Cardiac dysfunction (LVEF <50%) — limits anthracycline OR trastuzumab (HER2+ serous varia...RF-ENDOMETRIAL-TRANSFORMATION-PROGRESSION- Sarcomatoid transformation OR carcinosarcoma — distinct biology requiring different chemo...RF-IATROGENIC-COMBINED-HRT-PREVENTION- Cumulative use of combined hormone replacement therapy (estrogen + progestin / progestoge...RF-IATROGENIC-TAMOXIFEN-ENDOMETRIAL-PREVENTION- Current or prior tamoxifen exposure ≥5 years in a woman with intact uterus (no prior hyst...RF-LIFESTYLE-OBESITY-CANCER-PREVENTION- Obesity — BMI ≥30 kg/m² (per WHO definition) — OR class 2/3 obesity with BMI ≥35 / ≥40. I...RF-LIFESTYLE-SEDENTARY-PREVENTION- Low physical activity / sedentary lifestyle — defined as <150 min/week moderate-intensity...RF-LIFESTYLE-SUGARY-BEVERAGES-PREVENTION- High habitual intake of sugar-sweetened beverages (SSBs) — sodas, fruit drinks, sports dr...RF-LYNCH-CONFIRMED-CARRIER- Confirmed germline pathogenic / likely-pathogenic variant in a Lynch syndrome (MMR / EPCA...RF-LYNCH-FAMILY-HISTORY-SUSPICION- Family pedigree meeting criteria suggestive of hereditary nonpolyposis colorectal cancer...RF-POLE-POLD1-ENDOMETRIAL-LOW-RISK- Stage I endometrial carcinoma with pathogenic POLE or POLD1 exonuclease-domain mutation (...RF-REPRODUCTIVE-BREAST-ENDOMETRIAL-PREVENTION- Reproductive-history risk factors for hormone-driven cancers (breast + endometrial + ovar...RF-REPRODUCTIVE-OCP-LONG-TERM- Long-term combined oral contraceptive use (≥10 cumulative years). Mixed cancer risk profi...RF-REPRODUCTIVE-PCOS-ENDOMETRIAL-PREVENTION- Polycystic ovary syndrome (PCOS) with persistent anovulation and resulting chronic unoppo...
Sources
SRC-CHEN-MMRPRO-2006- Prediction of germline mutations and cancer risk in the Lynch syndrome (MMRpro)SRC-ESGO-ENDOMETRIAL-2025- ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: upda...SRC-ESMO-ENDOMETRIAL-2022- ESMO-ESGO-ESTRO Endometrial ConsensusSRC-NCCN-UTERINE-2025- NCCN Uterine Neoplasms